Company Overview of Genentech, Inc.
Genentech, Inc., a biotechnology company, engages in the research, discovery, development, manufacture, and marketing of biotechnology products using human genetic information for patients with serious or life-threatening diseases in the United States. The company focuses on developing monoclonal antibodies, small molecules, and antibody drug conjugates for use in various therapeutic areas, such as cardiovascular, immunology, infectious diseases, metabolism, neuroscience, oncology, ophthalmic diseases, biomarker assay technologies, and therapeutic lead discovery technologies. It also offers Xolair (omalizumab) for the treatment of chronic idiopathic urticaria. Genentech, Inc. has a strategic...
1 DNA Way
South San Francisco, CA 94080-4990
Founded in 1976
Key Executives for Genentech, Inc.
Co-Founder and Member of Scientific Resource Board
Executive Vice President of Research & Early Development and Member of Executive Committee
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Genentech, Inc. Key Developments
FDA Approves Genentech's Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Aug 14 14
Genentech, Inc. announced that the U.S. Food and Drug Administration approved Avastin(R) (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix. With this approval in advanced cervical cancer, Avastin is approved in the United States to treat five distinct tumor types. The approval in advanced cervical cancer was based on the GOG-0240 study.
Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
Aug 8 14
Genentech announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucentis(R) (ranibizumab injection) to the U.S. Food and Drug Administration (FDA) for the treatment of diabetic retinopathy. The submission is based on results of the RISE and RIDE Phase III clinical trials demonstrating the safety and efficacy of Lucentis for this serious eye disease. There are currently no ocular medications approved for the treatment of diabetic retinopathy. Diabetic retinopathy is the most common diabetic eye disease, impacting nearly 7.7 million Americans. The longer a person has diabetes, especially if it is poorly controlled, the higher the risk for developing diabetic retinopathy. It eventually affects nearly all diabetes patients and if left untreated, can lead to blindness. This eye disease is the leading cause of new cases of blindness in working-age Americans. More than 29 million Americans have diabetes.
Incyte Corporation Announces Clinical Trial Agreement with Genentech to Evaluate Combination of Two Novel Cancer Immunotherapies
Jul 30 14
Incyte Corporation announced that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech's PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC). Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer; both agents target distinct regulatory components of the immune system. Under the terms of the collaboration, Incyte and Genentech will collaborate on a non-exclusive basis to evaluate the combination. Incyte will be responsible for conducting the study and the results will be used to determine whether further clinical development of this combination is warranted.
Similar Private Companies By Industry
Recent Private Companies Transactions